You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Biocatalytic production of precursors to lutein and zeaxanthin to address age related macular degeneration

    SBC: EscaZyme Biochemicals, LLC            Topic: N

    Project Summary Atrophic dry age related macular degeneration AMD is the leading cause of severe loss of vision for those over age Dietary supplements containing lutein and zeaxanthin are recommended by the NEI for those at risk of late AMD There has been a corresponding growth in demand for these two xanthophylls Lutein and zeaxanthin are currently sourced from marigolds grown mostl ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Evidence-Based Pain Intervention for Veterans: Leveraging Mobile and Social Media

    SBC: Pro-Change Behavior Systems, Inc.            Topic: NCCIH

    Chronic musculoskeletal pain creates a significant public health burden, and Veterans are disproportionately affected. The frequency and extent of co-occurrence of pain and PTSD, pain and Traumatic Brain Injury (TBI), all three conditions (Post-deployment Multi-symptom Disorder (PMD), and other multi-symptom syndromes can complicate and reduce the effectiveness of pain treatment. Furthermore, the ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Novel Antigen-Specific Immunomodulatory Tregitope-based Therapy to Address Autoimmune Pathogenesis in Graves' Disease

    SBC: EPIVAX, INC.            Topic: 200

    ABSTRACT SignificanceGravesdiseaseGDone of the most prevalent autoimmune diseasesis caused by stimulating autoantibodiesTSAbto the Thyroid Stimulating Hormone ReceptorTSHRresulting in hyperthyroidismCurrent methods for managing hyperthyroidism in GD target excess thyroid hormone secretion by ablation or removal of the thyroid or by blocking thyroid hormone synthesisEach of these therapies is assoc ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Patient Engagement Alcohol Risk Reduction System PEARRS

    SBC: VERMEDX, INC.            Topic: 450

    PROJECT SUMMARY ABSTRACT Over a quarter of primary care patients in the United States can be classified as unhealthy drinkers because their alcohol use conveys a high risk of health and social consequences Unfortunately unhealthy drinking is under recognized in spite of the existence of valid screening tools Even when unhealthy drinking is recognized barriers such as provider discomfort shor ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Developing Testing and Validating a Wearable Alcohol Biosensor

    SBC: Clinitech, LLC            Topic: 450

    PROJECT SUMMARY This application for a Phase I SBIR award represents a collaboration between Clinitech LLC and McLean Hospital Harvard Medical School to develop a wearable biosensor for detecting alcohol in the interstitial fluid of humans who have consumed alcohol Excessive use of alcohol accounts for much of the public health burden related to alcohol use disorders including fetal ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Inter-alpha Inhibitors in Hypoxic-Ischemic Brain Injury

    SBC: PROTHERA BIOLOGICS, INC.            Topic: 105

    Neonatal hypoxia ischemiaHIremains a major cause of acute perinatal brain injuryleading ultimately to neurologic dysfunction manifesting as cerebral palsymental retardationand epilepsyUnfortunatelycurrent treatment and prevention strategies in newborns are limitedThere are no currently available therapies to prevent treat and or attenuate brain damage in premature infants other than supportive car ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Evaluating the Comparative Validity and Reliability of SERAS A Decision Support Tool for Assessing Near Term Risk of Suicide in Emergency Departments

    SBC: Wiser Systems LLC            Topic: 104

    PROJECT SUMMARY The goal of the NIMH Zero Suicide Initiative is prevention of suicide among individuals being served by health care systems The Products to Support Applied Research Towards Zero Suicide Healthcare Systems FOA specifically calls for development of health IT products designed to meet this goal Our Systematic Expert Risk Assessment of Suicide SERAS is a neural network based dec ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Automated 3D quantitative analysis of dendritic spines imaged with light microsco

    SBC: MICROBRIGHTFIELD, LLC            Topic: NIMH

    DESCRIPTION provided by applicant In this Lab to Marketplace proposal we aim to develop the MBF SpineStudio software incorporating the innovative laboratory based NeuronStudio software created at the Mount Sinai School of Medicine Our SpineStudio software will enable automated detection reconstruction and morphological classification of the structural analysis of dendritic spines By creating this ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Biomarker discovery for immunodiagnosis of invasive candidiasis

    SBC: DXDISCOVERY INC            Topic: NIAID

    DESCRIPTION (provided by applicant): Invasive candidiasis (IC) is one of the most serious threats to patients in a critical setting. With as many as 60,000 cases per year in the U.S., the total cost associated with IC in the U.S. may be as high as 2-4 billion/year. One of the most critical factors influencing patient outcome is early diagnosis. The goal of this project is a rapi and inexpensive i ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. An Automated Platform for High-throughput Network Electrophysiology

    SBC: CALISTA THERAPEUTICS INC            Topic: NHLBI

    DESCRIPTION (provided by applicant): Calista Therapeutics has discovered a first-in-class, proprietary PDZ1-2 lead drug, AT010, that is being optimized and developed as an inhaled daily therapy for cystic fibrosis (CF). CF is a deadly inherited genetic disorder that disrupts chloride channel function, resulting in the buildup of sticky mucus in patient's lungs and other organs.CF patients hav ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government